Sidley Represents Telix Pharmaceuticals in Its US$1.65 Billion Merger With ITM

Sidley is representing global radiopharmaceutical company Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) in its US$1.65 billion acquisition of ITM Isotope Technologies Munich SE, a radiopharmaceutical company based in Germany that specializes in radioisotope production and radiopharmaceutical development. The transaction will expand Telix’s isotope production and global manufacturing capabilities and add ITM’s complementary therapeutic pipeline. The transaction includes additional contingent consideration of up to US$700 million based on specified regulatory approvals and commercial sales milestones.

The Sidley team is being led in the U.S. by Sharon Flanagan, Pran Jha, and Ellen Hunter, and in Germany by Björn Holland (M&A and Private Equity), Trevor Wear (Healthcare), and Natalie Karam (Capital Markets) and includes Alex Enion, Jennifer Limmer, Adrienn Portnoy, Tobias Bachmeier, AJ San Diego, Milena Schoser, and Sarah Braun (M&A and Private Equity); Raj Pai, Josefine Sommer, Anna-Shari Melin, Julea Lipiz, and Alix Vermulst (Food, Drug and Medical Device); Lila Hope, Jiqiang (JQ) Lin, and Yuhan Wu (Technology and Life Sciences Transactions); Jörg Fischer, Suresh Advani, Jakob Nützel, and Zachary Tarnow (Tax); William RM Long, Ash Nagdev, Matthias Bruynseraede, and Ben Cross (Privacy and Cybersecurity); Elizabeth Hardcastle and Kim Schroer (Healthcare); Jason Semmes, Corey Roush, Murray Reeve, and Dominique Vletter (Antitrust and Competition); Angela Fontana, Robert Bennett Jr., Christian Axhausen, and Kyle Gromann (Global Finance); Lauren Gallagher, Matthew Green, and Joanna Janica (Employee Benefits and Executive Compensation); Sven De Knop, James Mendenhall, Maryanne Kamau, and Mine Orer (CFIUS/FDI); Natalie Chan and Kristina Daisak (Labor, Employment and Immigration); Heather Palmer and Austin Pierce (Environmental, Health, and Safety); and Scott Goldstein (Insurance).